MX2023012460A - Una forma de tafamidis en estado solido y un proceso para su preparacion. - Google Patents
Una forma de tafamidis en estado solido y un proceso para su preparacion.Info
- Publication number
- MX2023012460A MX2023012460A MX2023012460A MX2023012460A MX2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- tafamidis
- solid state
- state form
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382362.8A EP4083027A1 (en) | 2021-04-26 | 2021-04-26 | A solid state form of tafamidis and a process for its preparation |
| PCT/EP2022/060716 WO2022229026A1 (en) | 2021-04-26 | 2022-04-22 | A solid state form of tafamidis and a process for its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012460A true MX2023012460A (es) | 2023-12-14 |
Family
ID=75746555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012460A MX2023012460A (es) | 2021-04-26 | 2022-04-22 | Una forma de tafamidis en estado solido y un proceso para su preparacion. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240208915A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4083027A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7881608B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN117255781A (cg-RX-API-DMAC10.html) |
| BR (1) | BR112023022116A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3216325A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023012460A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022229026A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023091534A1 (en) * | 2021-11-17 | 2023-05-25 | Teva Pharmaceuticals International Gmbh | Solid state form of tafamidis |
| WO2026159144A1 (en) | 2025-01-22 | 2026-07-30 | Inke, S.A. | Solid forms of tafamidis methyl ethyl ketone solvate and processes for their manufacture |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1587821T6 (da) | 2002-12-19 | 2025-05-26 | Scripps Research Inst | Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning |
| KR20130079353A (ko) * | 2010-04-21 | 2013-07-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체 |
| WO2013038351A1 (en) | 2011-09-16 | 2013-03-21 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
| HUE056583T2 (hu) | 2014-09-08 | 2022-02-28 | Pfizer | 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| HRP20250159T1 (hr) | 2019-05-16 | 2025-03-28 | Assia Chemical Industries Ltd. | Kruti oblici tafamidisa i njegovih soli |
| WO2021001858A1 (en) * | 2019-07-04 | 2021-01-07 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021019448A1 (en) | 2019-08-01 | 2021-02-04 | Honour (R&D) | Process for the preparation of transthyretin dissociation inhibitor |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| WO2022084790A1 (en) * | 2020-10-19 | 2022-04-28 | Glenmark Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
-
2021
- 2021-04-26 EP EP21382362.8A patent/EP4083027A1/en not_active Withdrawn
-
2022
- 2022-04-22 WO PCT/EP2022/060716 patent/WO2022229026A1/en not_active Ceased
- 2022-04-22 US US18/288,195 patent/US20240208915A1/en active Pending
- 2022-04-22 EP EP22724736.8A patent/EP4330237A1/en active Pending
- 2022-04-22 CA CA3216325A patent/CA3216325A1/en active Pending
- 2022-04-22 JP JP2023565586A patent/JP7881608B2/ja active Active
- 2022-04-22 CN CN202280030391.4A patent/CN117255781A/zh active Pending
- 2022-04-22 BR BR112023022116A patent/BR112023022116A2/pt unknown
- 2022-04-22 MX MX2023012460A patent/MX2023012460A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117255781A (zh) | 2023-12-19 |
| BR112023022116A2 (pt) | 2024-01-09 |
| JP2024515770A (ja) | 2024-04-10 |
| EP4330237A1 (en) | 2024-03-06 |
| EP4083027A1 (en) | 2022-11-02 |
| CA3216325A1 (en) | 2022-11-03 |
| JP7881608B2 (ja) | 2026-06-29 |
| WO2022229026A1 (en) | 2022-11-03 |
| US20240208915A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL318601A (en) | Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C | |
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| AR063710A1 (es) | Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden. | |
| ZA202407964B (en) | Processes for preparing ag-10, its intermediates, and salts thereof | |
| WO2012065114A3 (en) | Polyketal adducts, methods of manufacture and uses thereof | |
| ZA202311094B (en) | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use | |
| WO2021016220A3 (en) | Synthesis of substituted furans | |
| SI1601653T1 (sl) | Postopek za pripravo substituiranih estrov nikotinske kisline | |
| MX378594B (es) | Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos | |
| BR112023022116A2 (pt) | Uma forma em estado sólido de tafamidis e um processo para sua preparação | |
| AR116423A1 (es) | Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino | |
| DK1877384T3 (da) | Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer | |
| WO2020016847A3 (en) | Purification process for preparation of eribulin and intermediates thereof | |
| MX2025009371A (es) | Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello | |
| MX2025014399A (es) | Sintesis de acil sulfoximinas ciclicas | |
| EA202192581A1 (ru) | Композиции d-метирозина и способы их получения | |
| US3922281A (en) | Process for the preparation of 3-(O,O-diethyldithiophosphorylmethyl)-6-chloro-benzoxazolone | |
| MX2024014493A (es) | Formas solidas de heterociclilamidas como inhibidores de irak4 | |
| SE7907455L (sv) | Nytt forfarande for framstellning av vissa cefemforeningar | |
| TW202617700A (zh) | 用於製備4-胺基-呋喃之方法 | |
| MX2024003962A (es) | Procedimiento para preparar compuestos activos tipo sartanes que tienen un anillo de tetrazol. | |
| MX2023010998A (es) | Un compuesto de quinolona en formas solidas y procesos para su preparacion. | |
| MX2025000464A (es) | Forma cristalina de un esteroide neuroactivo | |
| MX2024007679A (es) | Compuestos intermedios cristalinos. | |
| WO2024186788A3 (en) | High purity nitric oxide releasing compounds and methods of preparing same |